Dr Reddy’s seeks approval from Health Canada for Favipiravir

By: |
December 22, 2020 1:00 PM

The application was filed under Health Canada's "Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19," a release from the city-based drug maker said.

Favipiravir, covid 19According to Health Canada, Reeqonu (favipiravir) Tablets are the first oral solid dosage form submitted under the Interim Order for the acute treatment of mild to moderate COVID-19 adult patients. (Photo source: Reuters)

Dr Reddy’s Laboratories Ltd, Canada-based Appili Therapeutics and Dubai-based Global Response Aid FZCO (GRA) on Tuesday said Dr Reddy’s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) Tablets for treating COVID-19 in the North American country.

The application was filed under Health Canada’s “Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19,” a release from the city-based drug maker said. Reequnus is also known as Avigan (favipiravir) Tablets developed by Fujifilm Toyama Chemical Co., Ltd. “We are pleased to work with our partners at GRA and Appili to be the first in Canada to file an application for oral solid tablets for COVID-19 treatment under Health Canadas Interim Order,” Vinod Ramachandran Vice President and General Manager, Dr. Reddys Laboratories Canada Inc said.

Dr. Reddy’s is working closely with Health Canada for an expedited review of the drug application, as speed to market is essential in these unprecedented times. If approved, the drug will be launched soon to benefit the lives and health of COVID-19 patients in Canada, he said.

“Our role remains to design rigorous trials to obtain the data that identify COVID-19 patients that may benefit from Reeqonus. We look forward to working with our partners in providing information to Health Canada with the goal of advancing this important innovation for patients,” Armand Balboni, Chief Executive Officer of Appili Therapeutics said.

“Our outreach to Canada is a part of our global efforts to play an active role in addressing the COVID-19 situation. The filing is a testimony to our commitment of bringing a potential solution to COVID-19 for the Canadian population, Chief Executive Officer of GRA, Mitch Wilson said.

In September, the Interim Order respecting the importation, sale and advertising of drugs for use in relation to COVID-19 was signed by the Minister of Health in Canada to create a new authorization pathway that will help expedite the authorization of drugs and vaccines for COVID-19.

According to Health Canada, Reeqonu (favipiravir) Tablets are the first oral solid dosage form submitted under the Interim Order for the acute treatment of mild to moderate COVID-19 adult patients.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid-19: Botswana scientist who sequenced Omicron variant worried by pace of mutation
2Half of India’s adult population fully vaccinated against COVID-19
3Coronavirus Omicron India Live Updates: Omicron patient in Maharashtra had taken both doses of Covid vaccine, India’s total tally of Omicron cases reaches 5